{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:32:59Z","timestamp":1793305979618,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104844","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:57:19Z","timestamp":1792652239000},"page":"104844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PARP-1 selective inhibitors: A new direction in drug discovery to improve the therapeutic index of PARP-targeted cancer therapy"],"prefix":"10.1016","volume":"31","author":[{"given":"Eman M.","family":"Elkafoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek F.","family":"El-Moselhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat H.","family":"El-Hamamsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman A.","family":"El-Bastawissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6479-4573","authenticated-orcid":false,"given":"Hamada S.","family":"Abulkhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104844_b0005","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","article-title":"PARP inhibitors for breast cancer treatment","volume":"10","author":"Morganti","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.drudis.2026.104844_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104803","article-title":"Synthetic lethality and context-selective DNA-damage response dependencies: from genetic vulnerability to pharmacological translation","volume":"31","author":"Jo","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104844_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107924","article-title":"Synergy trap for guardian angels of DNA: unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition","volume":"153","author":"Elkafoury","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118743","article-title":"InhibitWin duo: rational design and structural insights into dual PARP\/HDAC inhibitors for synergistic DNA repair disruption and epigenetic modulation","volume":"309","author":"Elkafoury","year":"2026","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bulcan.2026.04.009","article-title":"Comment pr\u00e9venir et g\u00e9rer les toxicit\u00e9s h\u00e9matologiques li\u00e9es aux inhibiteurs de PARP dans le cancer de la prostate\u00a0?","volume":"113","author":"Cassuto","year":"2026","journal-title":"Bull Cancer"},{"key":"10.1016\/j.drudis.2026.104844_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.119047","article-title":"Single versus dual EGFR\/PARP inhibition: mechanistic rationale, synthetic approaches, pharmacophoric features, structure\u2013activity relationships, and therapeutic perspectives","volume":"316","author":"Elkafoury","year":"2026","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0035","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1021\/acs.jmedchem.5c00185","article-title":"Discovery and pharmacological evaluation of potent and highly selective PARP1 inhibitors","volume":"68","author":"Guo","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu8849","article-title":"PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity","volume":"12","author":"Mart\u00ednez-Bosch","year":"2026","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2026.104844_b0045","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.ajpath.2025.07.004","article-title":"Poly(ADP-ribose) polymerase 1 and 2 in B-cell lymphoma","volume":"195","author":"Molina-Alvarez","year":"2025","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2026.104844_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10555-025-10283-1","article-title":"Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety meta-analysis","volume":"44","author":"Maiorano","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.drudis.2026.104844_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1012062","article-title":"PARP-2 catalytic activity drives replication-ICL repair in an allele-specific manner during germline development","volume":"22","author":"Ren","year":"2026","journal-title":"PLoS Genet"},{"key":"10.1016\/j.drudis.2026.104844_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2026.118757","article-title":"Discovery of DA1 as PARP inhibitor for the treatment of BRCA-proficient triple negative breast cancer by suppressing the PI3K\/AKT\/mTOR signaling pathway","volume":"141","author":"Qu","year":"2026","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0065","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14796694.2026.2655433","article-title":"Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01","volume":"22","author":"Azad","year":"2026","journal-title":"Futur Oncol"},{"key":"10.1016\/j.drudis.2026.104844_b0070","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/cells15070588","article-title":"PARP inhibition in prostate cancer: current status, resistance mechanisms, and clinical challenges","volume":"15","author":"Matsuoka","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104844_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117466","article-title":"PARP1-specific inhibitor displays PARP1-detrapping activity","volume":"45","author":"Sch\u00fctzenhofer","year":"2026","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2026.104844_b0080","first-page":"788","article-title":"Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives","volume":"23","author":"Yu","year":"2026","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.drudis.2026.104844_b0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription\u2013replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104844_b0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104844_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70182","article-title":"Physiologically\u2010based pharmacokinetic modeling of the PARP inhibitor niraparib","volume":"15","author":"Lewis","year":"2026","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.drudis.2026.104844_b0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s43556-025-00385-1","article-title":"PARPs and PARP inhibitors: molecular mechanisms and clinical applications","volume":"6","author":"Wang","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.drudis.2026.104844_b0105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14737140.2024.2357822","article-title":"Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis","volume":"24","author":"Dai","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.drudis.2026.104844_b0110","doi-asserted-by":"crossref","first-page":"19248","DOI":"10.1021\/acs.jmedchem.6c01564","article-title":"Structural modification and prodrug design based on natural stilbene scaffold for the discovery of novel PARP-1 inhibitors with improved antitumor activity","volume":"69","author":"Zou","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1713069","article-title":"Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review","volume":"16","author":"Dima","year":"2026","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104844_b0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin Oncol"},{"key":"10.1016\/j.drudis.2026.104844_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0115680096327635241021115944","article-title":"Clinical application of PARP1 inhibitors and challenges in cancer therapy","volume":"26","author":"Luo","year":"2026","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.drudis.2026.104844_b0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s43094-026-00984-x","article-title":"PARP-1 inhibitors in cancer therapy: design, molecular modeling, structure\u2013activity relationships, and clinical advances","volume":"12","author":"Abdullah","year":"2026","journal-title":"Futur J Pharm Sci"},{"key":"10.1016\/j.drudis.2026.104844_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102629","article-title":"PARP inhibitor plus androgen-receptor signaling inhibitor versus the same inhibitor alone in homologous-recombination-repair-altered metastatic prostate cancer across the hormone-sensitive and castration-resistant continuum: a systematic review and meta-A","volume":"24","author":"Su","year":"2026","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.drudis.2026.104844_b0140","doi-asserted-by":"crossref","first-page":"20651","DOI":"10.1021\/acs.jmedchem.6c01400","article-title":"Optimization of a second-generation, highly selective Pol\u03b8\/PARP1 dual inhibitor with improved pharmacokinetics and potent activity against HR-deficient tumors","volume":"69","author":"Ma","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0145","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","article-title":"Preclinical characterization of AZD9574, a blood\u2013brain barrier penetrant inhibitor of PARP1","volume":"30","author":"Staniszewska","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104844_b0150","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1038\/s44319-026-00848-8","article-title":"PARG inhibition reduces ssDNA levels and limits RPA loading upon replication fork collapse","volume":"27","author":"Mihu\u021b","year":"2026","journal-title":"EMBO Rep"},{"key":"10.1016\/j.drudis.2026.104844_b0155","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104844_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113898","article-title":"Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2","volume":"227","author":"Yu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0165","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-4201","article-title":"Combination of the PARP1-selective inhibitor saruparib with androgen receptor pathway inhibition provides combination benefit in preclinical models of prostate cancer with or without homologous recombination repair deficiency","volume":"85","author":"Albertella","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104844_b0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40364-026-00908-0","article-title":"Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective","volume":"14","author":"Xiang","year":"2026","journal-title":"Biomark Res"},{"key":"10.1016\/j.drudis.2026.104844_b0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/pharmaceutics18030355","article-title":"Interplay between poly(ADP-ribosyl)ation and specific inner cellular events that suggest combination strategies for overcoming PARP inhibitor resistance","volume":"18","author":"Xu","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104844_b0180","doi-asserted-by":"crossref","first-page":"22033","DOI":"10.1021\/acs.jmedchem.5c01512","article-title":"Emerging molecular PET imaging for cell death in neurodegenerative diseases","volume":"68","author":"Zhang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0185","doi-asserted-by":"crossref","first-page":"21380","DOI":"10.1021\/acs.jmedchem.4c02276","article-title":"Discovery of pyrazolo[1,5,4-de]quinoxalin-2(3H)-one derivatives as highly potent and selective PARP1 inhibitors","volume":"67","author":"Gao","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0190","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.drudis.2021.08.007","article-title":"Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: current situation and future directions","volume":"27","author":"Jin","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104844_b0195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.drudis.2026.104844_b0200","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3390\/molecules31101592","article-title":"Structural determinants of PARP1 selectivity from molecular dynamics analysis of PARP1 and PARP2 complexes","volume":"31","author":"Shkil","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104844_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106255","article-title":"Exploring the dual effect of novel 1,4-diarylpyranopyrazoles as antiviral and anti-inflammatory for the management of SARS-CoV-2 and associated inflammatory symptoms","volume":"130","author":"Malebari","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0210","doi-asserted-by":"crossref","first-page":"0033","DOI":"10.5152\/cjm.2026.26033","article-title":"Hematologic toxicity during first-line platinum-based chemotherapy in BRCA-mutated ovarian cancer: predictors and survival I mpact","volume":"50","author":"\u00c7okgezer","year":"2026","journal-title":"Cerrahpa\u015fa Med J"},{"key":"10.1016\/j.drudis.2026.104844_b0215","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1021\/acs.biochem.6c00019","article-title":"Mechanistic insights into the stimulation of Arabidopsis PARP2 self-parylation catalytic activity by DNA breaks and PAR","volume":"65","author":"Greeshma","year":"2026","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104844_b0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/bloodadvances.2025017375","article-title":"Induction of moderate DNA damage enhances megakaryopoiesis and platelet production","volume":"10","author":"Camacho","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2026.104844_b0225","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2026.1924","article-title":"Long-term outcomes in patients with recurrent ovarian cancer and exceptional response to PARP inhibitors","volume":"12","author":"Haggstrom","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.drudis.2026.104844_b0230","article-title":"Real-world management of ovarian cancer in women living with HIV: treatment exposure, immune monitoring, and care barriers in a five-case series","volume":"16","author":"Zhang","year":"2026","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104844_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1894818","article-title":"From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors","volume":"16","author":"Ayoub","year":"2026","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104844_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.caneu.2026.100002","article-title":"Revitalizing 5-ethynyl-2\u2032-deoxyuridine (EdU) for glioblastoma: from phenotypic suppression to the \u201cfutile cycle\u201d of nucleotide excision repair","author":"Alomari","year":"2026","journal-title":"Cancer Neurosci"},{"key":"10.1016\/j.drudis.2026.104844_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.110048","article-title":"Beyond PARP-HDAC inhibition: mechanistic rationale and medicinal chemistry insights from single to shared-target strategies","volume":"180","author":"Elkafoury","year":"2026","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104694","article-title":"Ligand trapping as a key mechanism governing drug residence time, binding affinity, and potency","volume":"31","author":"Spassov","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104844_b0255","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12609-025-00582-5","article-title":"Targeting PARP1: a promising approach for next-generation poly (ADP-ribose) polymerase inhibitors","volume":"17","author":"Ray","year":"2025","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.drudis.2026.104844_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.110204","article-title":"Potent and isoform-selective PARP1 degraders for the treatment of BRCA-deficient cancers","volume":"180","author":"Sun","year":"2026","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104844_b0265","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1021\/acsmedchemlett.5c00536","article-title":"Development of selective PARP1 inhibitors for treatment of cancer","volume":"16","author":"Zhou","year":"2025","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104844_b0270","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1021\/acschembio.5c01021","article-title":"Noncovalent PAR binding guides proteins to PARP1-mediated PARylation","volume":"21","author":"Fischbach","year":"2026","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104844_b0275","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41401-026-01848-z","article-title":"Endothelial PARP1 orchestrates endothelial-to-mesenchymal transition via the PARylation of FHL2 in ischaemic heart failure","volume":"47","author":"Su","year":"2026","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2026.104844_b0280","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400140","article-title":"KAT6A condensates impair PARP1 trapping of PARP inhibitors in ovarian cancer","volume":"11","author":"Zhan","year":"2024","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2026.104844_b0285","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.3390\/ijms27156754","article-title":"PARP inhibitor sensitivity in tumors harboring non-BRCA homologous recombination gene alterations: current evidence across ovarian, breast, prostate, and pancreatic cancers","volume":"27","author":"dos Santos","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104844_b0290","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.62347\/KYXG9110","article-title":"PARP inhibitor maintenance in first-line ovarian cancer therapy: emerging standards and strategies to overcome resistance","volume":"16","author":"Chen","year":"2026","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.drudis.2026.104844_b0295","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1007\/s00259-026-08016-9","article-title":"Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects","volume":"53","author":"Kurniawan","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.drudis.2026.104844_b0300","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s11033-026-12223-w","article-title":"Decoding PARP roles in breast cancer therapy resistance","volume":"53","author":"Abohassan","year":"2026","journal-title":"Mol Biol Rep"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:21:11Z","timestamp":1793305271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002497"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104844","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP-1 selective inhibitors: A new direction in drug discovery to improve the therapeutic index of PARP-targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104844"}}